

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 221/06, A61K 31/44		A1	(11) International Publication Number: WO 94/21614 (43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: PCT/US94/03080 (22) International Filing Date: 22 March 1994 (22.03.94) (30) Priority Data: 036,645 24 March 1993 (24.03.93) US (60) Parent Application or Grant (63) Related by Continuation US 036,645 (CON) Filed on 24 March 1993 (24.03.93) (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GRAHAM, Donald, W. [US/US]; 294 Old Tote Road, Mountainside, NJ 07092 (US). HAGMANN, William, K. [US/US]; 871 Shackamaxon Drive, Westfield, NJ 07090 (US). (74) Agent: QUAGLIATO, Carol, S.; Merck & Co., Inc., Patent Department, 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5 α -REDUCTASE INHIBITORS

(57) Abstract

Compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein R₁ and R₃ are selected from the group consisting of hydrogen and C₁₋₆ alkyl; R₂ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylcarbonyloxy; X is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆ alkyl, halogen, cyano, C₁₋₆ alkylcarbonyl, Ar-carbonyl, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkylaminocarbonyl, Ar-aminocarbonyl and di-C₁₋₆ alkylaminocarbonyl; and Ar is phenyl and pyridyl. Such compounds are useful in the treatment of pathologic conditions that benefit from blockade of isozymes of 5 α -reductase.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION**SUBSTITUTED 3-PHENANTHRIDINONE****DERIVATIVES AS 5α - REDUCTASE INHIBITORS****5 FIELD OF THE INVENTION**

The present invention provides novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the selective inhibition
10 of the isozyme 5α -reductase 1.

BACKGROUND OF THE INVENTION

Certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness
15 (alopecia) and benign prostatic hyperplasia, are the result of hyperandrogenic stimulation caused by an excessive accumulation of testosterone or similar androgenic hormones in the metabolic system. Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of
20 several steroidal antiandrogens having undesirable hormonal activities of their own. The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethyl-isobutyranilide. See Neri, *et al.*, *Endocrinol.* **1972**, 91
25 (2). However, these products, though devoid of hormonal effects, compete with all natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male fetus of a female host and/or initiate feed-back effects which would cause hyperstimulation of the testes.

30 The principal mediator of androgenic activity in some target organs, e.g. the prostate, is 5α -dihydrotestosterone, formed locally in the target organ by the action of testosterone- 5α -reductase. Inhibitors of testosterone- 5α -reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation in these organs. It is now


- 2 -

known that a second 5 α -reductase isozyme exists, which interacts with epidermal tissues, especially in scalp tissues. This form is conventionally designated as 5 α -reductase 1, while the isozyme that principally interacts with the prostatic tissues is designated as 5 α -
5 reductase 2. Both isozymes are active in the prostatic tissues. Thus, in the treatment of hyperandrogenic disease conditions e. g. benign prostatic hyperplasia (BPH), it would be desirable to have one drug entity which is active against both isozymes in the prostate to significantly inhibit dihydrotestosterone production, while also having
10 another drug entity which is highly selective for inhibiting the isozyme 5 α -reductase 1 associated with the scalp, for use in treating conditions of the skin and scalp, e. g. acne and alopecia in males and hirsutism in females. Additionally, such a selective 5 α -reductase 1 inhibitor could also be used in combination with finasteride (PROSCAR®), which is
15 highly selective for 5 α -reductase 2, for combination therapy in the treatment of BPH. Therefore it is an object of this invention to provide compounds that have sufficient activity in the inhibition of one or both 5 α -reductase isozymes. It is an additional object of this invention to provide compounds that are useful in the treatment and/or prevention of
20 benign prostatic hyperplasia. It is an additional object of this invention to provide compounds that are useful in the treatment of female hirsutism, male pattern baldness, acne, androgenetic alopecia, prostatic cancer, and insufficient plasma levels of high density lipoproteins. The compounds of the invention have utility in one or more of the
25 aforementioned areas.

SUMMARY OF THE INVENTION

The compounds of the present invention are those of the general structural formula I:

30



- 3 -

or a pharmaceutically acceptable salt or ester thereof,

wherein

5 R₁ and R₃ are independently selected from the group consisting of hydrogen and C₁-6 alkyl;

10 R₂ is selected from the group consisting of hydrogen, C₁-6 alkyl, C₁-6 alkoxy and C₁-6 alkylcarbonyloxy;

15 X is selected from the group consisting of hydrogen, C₁-6 alkyl, C₁-6 alkoxy, C₁-6 alkoxy-C₁-6 alkyl, halogen, cyano, C₁-6 alkylcarbonyl, Ar-carbonyl, C₁-6 alkoxy carbonyl, C₁-6 alkylaminocarbonyl, Ar-aminocarbonyl and di-C₁-6 alkylaminocarbonyl; and

Ar is phenyl or pyridyl.

DETAILED DESCRIPTION OF THE INVENTION

20 Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following salts:

25

30

- 4 -

	Acetate	Lactobionate
	Benzenesulfonate	Laurate
5	Benzoate	Malate
	Bicarbonate	Maleate
	Bisulfate	Mandelate
	Bitartrate	Mesylate
	Borate	Methylbromide
10	Bromide	Methylnitrate
	Calcium Edetate	Methylsulfate
	Camsylate	Mucate
	Carbonate	Napsylate
	Chloride	Nitrate
15	Clavulanate	N-methylglucamine ammonium salt
	Citrate	Oleate
	Dihydrochloride	Oxalate
	Edetate	Pamoate (Embonate)
	Edisylate	Palmitate
20	Estolate	Pantothenate
	Esylate	Phosphate/diphosphate
	Fumarate	Polygalacturonate
	Gluceptate	Salicylate
	Gluconate	Stearate
25	Glutamate	Sulfate
	Glycollylarsanilate	Subacetate
	Hexylresorcinat	Succinate
	Hydrabamine	Tannate
	Hydrobromide	Tartrate
30	Hydrochloride	Teoclate
	Hydroxynaphthoate	Tosylate
	Iodide	Triethiodide
	Isothionate	Valerate
	Lactate	

- 5 -

The term "pharmacologically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.

5 The term "alkyl" shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any specified numbers within this range.

10 Whenever the term "alkyl" or its prefix root appears in a name of a substituent (e.g. aralkoxyaryloxy) it shall be interpreted as including those limitations given above for "alkyl".

15 The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an antiandrogenic agent.

20 The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

30 Oral dosages of the present invention, when used for the indicated effects, will range between about 0.05 to 1000 mg/day orally. The compositions are preferably provided in the form of scored tablets containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0 and 50.0 mg of active ingredient. Effective plasma levels of the compounds of the present invention range from 0.002 mg to 50 mg per kg of body weight per

- 6 -

day. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

5 Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent
10 throughout the dosage regimen. Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of active ingredient would range from 0.1% to 15%, w/w or w/v.

15 In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
20

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary,
25 suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes
30 and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

- 7 -

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines.


Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxy-ethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

The compounds of the present invention can be prepared readily according to the following reaction Schemes and Examples or modifications thereof using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail.

30

- 8 -


Synthesis Scheme I



The carbonyl of a phenanthrone such as **1** is protected as the ketal **2** by reaction with ethylene glycol in the presence of an acid with removal of water. The double bond which moves out of conjugation with the aforementioned carbonyl is oxidized to the ozonide which is subsequently oxidized with hydrogen peroxide. The resulting acid **3** is converted to the acyl azide **5** via the acid chloride **4**. Heating of **5** results in a Curtius rearrangement to the isocyanate which, along with the ketal protecting group, is hydrolyzed in the presence of aqueous acid to the dione **6** which will spontaneously cyclize to the 3-phenan-

thridinone **7**. Alkylation of the nitrogen with an alkyl iodide results in the formation of **8**.

Synthesis Scheme II



30 In Scheme II, Michael addition of N-alkyl homophthalimide to phenylthiomethyl vinyl ketone in the presence of base gives the adduct **9**. The side chain carbonyl is protected as the ketal and one of the ring carbonyl groups is reduced with sodium borohydride and eliminated to form the isocarbostyryl or isoquinolone-like compound **11**. Subsequent ketalization of the side chain carbonyl followed by reduction and cyclization yields the substituted 3-phenanthridinone **12**.

- 10 -

Oxidative elimination of the phenylthio group gives the desired product **13**.

5 The most preferred compounds of the invention are any or all of those specifically set forth in these examples. These compounds are not, however, to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. The following examples further
10 illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless noted otherwise.

15

EXAMPLE 1

BIOLOGICAL ASSAYS

20 Preparation of Human prostatic and scalp 5 α -reductases

 Samples of human tissue were pulverized using a freezer mill and homogenized in 40 mM potassium phosphate, pH 6.5, 5 mM magnesium sulfate, 25 mM potassium chloride, 1 mM phenylmethyl-sulfonyl fluoride, 1 mM dithiothreitol (DTT) containing 0.25 M sucrose
25 using a Potter-Elvehjem homogenizer. A crude nuclear pellet was prepared by centrifugation of the homogenate at 1,500 xg for 15 min. The crude nuclear pellet was washed two times and resuspended in two volumes of buffer. Glycerol was added to the resuspended pellet to a final concentration of 20%. The enzyme suspension was frozen in
30 aliquots at -80°C. The prostatic and scalp reductases were stable for at least 4 months when stored under these conditions.

5 α -reductase assay

 The reaction mixture contained in a final volume of 100 μ l is: 40 mM buffer (human scalp, potassium phosphate, pH 6.5; human

- 11 -

prostatic 5 α -reductase, sodium citrate, pH 5.5), 0.3-10 μ M ¹⁴C-T (or ³H-T), 1 mM DTT, and 500 μ M NADPH. Typically, the assay was initiated by the addition of 50-100 μ g prostatic homogenate or 75-200 μ g scalp homogenate and incubated at 37°C. After 10-50 min the reaction was quenched by extraction with 250 μ l of a mixture of 70% cyclohexane: 30% ethyl acetate containing 10 μ g each DHT and T. The aqueous and organic layers were separated by centrifugation at 14,000 rpm in an Eppendorf microfuge. The organic layer was subjected to normal phase HPLC (10 cm Whatman partisil 5 silica column equilibrated in 1 ml/min 70% cyclohexane: 30% ethyl acetate; retention times DHT, 6.8-7.2 min; androstanediol, 7.6-8.0; T, 9.1-9.7 min). The HPLC system consisted of a Waters Model 680 Gradient System equipped with a Hitachi Model 655A autosampler, Applied Biosystems Model 757 variable UV detector, and a Radiomatic Model A120 radioactivity analyzer. The conversion of T to DHT was monitored using the radioactivity flow detector by mixing the HPLC effluent with one volume of Flo Scint 1 (Radiomatic). Under the conditions described, the production of DHT was linear for at least 25 min. The only steroids observed with the human prostate and scalp preparations were T, DHT and androstanediol.

EXAMPLE 2

A solution of 4a-methyl-4,4a,9,10-tetrahydro-2(3H)-phenanthrene **1** (7 g, 33 mmol; prepared by the method of A. L. Campbell and J. D. McChesney, *Syn. Commun.* **1979**, *9*, 471-479) is dissolved in anhydrous benzene (300 mL) and ethylene glycol (16 mL) and p-toluenesulfonic acid (0.7 g, 4 mmol) added. The solution is refluxed with the removal of water in a Dean-Stark trap according to the method of A. J. Vila, R. A. Spanevello, A. C. Olivieri, M. G. Sierra, and J. D. McChesney, *Tet. Lett.* **1989**, *45*, 4951-4960 to form the ketal, 2-ethylenedioxy-4a-methyl-1,2,3,4,4a,9-hexahydro-phenanthrene **2**.

- 12 -

A solution of **2** is dissolved in methylene chloride and cooled to -78°C and a stream of ozone is passed through it until a pale blue color persists. A solution of water containing 30% hydrogen peroxide is added and the mixture warmed to 0°C for 2 hr, then to room temperature for 48 hr. Ethyl acetate is added and the solution successively washed with 2% aqueous sodium bisulfite solution, water, and saturated salt solution. The organic solution is dried over anhydrous sodium sulfate and the solvent removed by rotoevaporation to yield 2-(4'-ethylenedioxy-1'-methyl-2'-oxocyclohexyl)-phenylacetic acid **3**.

The acid **3** is dissolved in diethyl ether and dimethylformamide and thionyl chloride is added. The solution is stirred at room temperature for 1 hr and poured into ice water. The ether layer is separated and dried over anhydrous sodium sulfate. The solvent is removed by rotoevaporation and the product, 2-(4'-ethylenedioxy-1'-methyl-2'-oxocyclohexyl)-phenylacetyl chloride **4**, is dissolved in acetone. Sodium azide is added and the solution stirred for 20 min. Water is added and the mixture extracted with diethyl ether and the organic layer dried over anhydrous sodium sulfate. The solvent is removed by rotoevaporation to yield 2-(4'-ethylenedioxy-1'-methyl-2'-oxocyclohexyl)-phenylacetyl azide **5**.

The acyl azide **5** is dissolved in dimethylformamide and heated to 100°C until nitrogen evolution ceases. The solution is cooled and treated with aqueous acetic acid to form 2-(2',4'-dioxo-1'-methylcyclohexyl)-benzyl amine **6**. Diethyl ether is added and the solution is washed successively with saturated sodium bicarbonate solution, water, and saturated salt solution and dried over anhydrous sodium sulfate. The solvent is removed by rotoevaporation to yield 1,2,3,4,4a,5,6,10b-octahydro-10b-methyl-3-phenanthridinone **7**.

A solution of **7** in dimethylformamide at 0°C is treated with 1 equivalent of sodium hydride followed by methyl iodide. After stirring at room temperature, diethyl ether is added and the solution successively washed with water and saturated salt solution. The solvent

- 13 -

is removed by rotoevaporation to yield 1,2,3,4,4a,5,6,10b-octahydro-5,10b-dimethyl-3-phenanthridinone **8**.

EXAMPLE 3

5

3(2H)-Phenanthridinone derivatives have been prepared from homophthalimide by the method of H. Iida *et al.*, (*Heterocycles* **1983**, *20*, 227-30). 2-Methyl-homophthalimide is reacted with phenylthiomethyl vinyl ketone (prepared by the method A. G. Schultz *et al.*, *J. Am. Chem. Soc.* **1978**, *100*, 2140-9) in the presence of Triton B according to the described method to form 2-methyl-4-(3'-oxo-4'-phenylthiobutyl)-homophthalimide **9**.

10

Reaction of **9** with ethylene glycol and p-toluenesulfonic acid in refluxing anhydrous benzene with removal of water by a Dean-Stark trap gives 4-(3'-ethylenedioxy-4'-phenylthiobutyl)-2-methyl-homophthalimide **10** which is reduced with sodium borohydride and treated with aqueous hydrochloric acid to form 2-methyl-4-(3'-oxo-4'-phenylthiobutyl)-isocarbostyryl **11**.

15

Ketalization of **11** with ethylene glycol in the presence of p-toluenesulfonic in refluxing benzene follows as above. Reaction of the ketal with lithium aluminum hydride in diethyl ether followed by treatment with concentrated hydrochloric acid at 100°C gives 5-methyl-1,2,3,4,4a,5,6,10b-octahydro-4-phenylthio-3-phenanthridinone **12**. Treatment of **12** with basic hydrogen peroxide gave 5-methyl-1,2,3,4,4a,10b-hexahydro-3-phenanthridinone **13**.

20

25

While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for any of the indications for the compounds of the invention indicated above.

30

- 14 -

Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

5
10

15

20


25

30

- 15 -

WHAT IS CLAIMED IS:

1. A compound of the formula I



or a pharmaceutically acceptable salt or ester thereof,

wherein

R₁ and R₃ are independently selected from the group consisting of hydrogen and C₁-6 alkyl;

R₂ is selected from the group consisting of hydrogen, C₁-6 alkyl, C₁-6 alkoxy and C₁-6 alkylcarbonyloxy;

X is selected from the group consisting of hydrogen, C₁-6 alkyl, C₁-6 alkoxy, C₁-6 alkoxy-C₁-6 alkyl, halogen, cyano, C₁-6 alkylcarbonyl, Ar-carbonyl, C₁-6 alkoxy carbonyl, C₁-6 alkylaminocarbonyl, Ar-aminocarbonyl and di-C₁-6 alkylaminocarbonyl; and

Ar is phenyl or pyridyl.

2. A method for inhibiting 5 α -reductase or the isozymes thereof, comprising the step of administering to a mammal in need of such inhibition a pharmacologically effective amount of the compound as claimed in Claim 1.

3. A method for treating, in a mammal in need thereof, the hyperandrogenic conditions of acne, androgenic alopecia, male pattern baldness, female hirsutism, benign prostatic hyperplasia,

- 16 -

prostatitis, and the treatment and prevention of prostatic cancer,
comprising the step of administering to said mammal a
pharmacologically effective amount of the compound as claimed in
Claim 1.

5

4. A pharmaceutical composition comprising a
pharmaceutically acceptable carrier and a pharmacologically effective
amount of a compound as claimed in Claim 1, sufficient to treat a
hyperandrogenic condition in a mammal in need of such treatment.

10

15

20

25

30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/03080

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C07D 221/06; A61K 31/44

US CL : 546/079; 514/290

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/079; 514/290

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ON LINE, BEILSTEIN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A, 3,567,733 (NOMINE ET AL.) 02 MARCH 1971,SEE ENTIRE DOCUMENT.	1
A,P	US,A, 5,247,091 (MUELLER-LEHAR) 21 SEPTEMBER 1993,SEE ENTIRE DOCUMENT.	1

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 MAY 1994

Date of mailing of the international search report

JUN 23 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ALAN L. ROTMAN

Telephone No. (703) 308-1235